Thrombosis
Commentary
Universal testing for Lp(a): What are we waiting for?
A resurgent interest in molecular pathophysiology this past decade has clarified Lp(a)’s unique contribution to atherothrombotic disease and...
From the Journals
After PCI, 1-month beats 12-month DAPT in high-risk patients
When dual was replaced by single antiplatelet therapy 1 month after PCI in Japanese patients, bleeding risk declined.
Latest News
Warfarin best for thrombotic antiphospholipid syndrome?
A vitamin K antagonist such as warfarin, rather than a direct oral anticoagulant, appears to be a better treatment for patients with thrombotic...
From the Journals
Statins tied to lower ICH risk regardless of bleed location
A large new case-control study has shown a reduced risk of both lobar and nonlobar intracerebral hemorrhage with statin use, providing reassurance...
Conference Coverage
No benefit of rivaroxaban in COVID outpatients: PREVENT-HD
PREVENT-HD joins a long list of smaller trials also showing no benefit of anticoagulation in nonhospitalized COVID-19 patients.
Conference Coverage
EHR-based thromboembolism risk tool boosted prophylaxis
A thromboembolism risk calculator in a hospital’s EHR led to a significant rise in appropriate thromboprophylaxis and a drop in thromboembolic...
Conference Coverage
Combo thrombolytic approach fails to reduce ICH in stroke
Although there were promising signs of a potential reduced bleeding risk in intracranial hemorrhage, the DUMAS study showed no benefit on the...
From the Journals
Best anticoagulant for minimizing bleeding risk identified
“Apixaban stood out as having lower risk of gastrointestinal bleeding.”
Conference Coverage
Collateral flow flags stroke patients for late thrombectomy
The MR CLEAN-LATE trial shows patients selected for thrombectomy on the presence of collateral flow had a greater chance of a better functional...
Feature
Apixaban outmatches rivaroxaban in patients with AFib and valvular heart disease
Compared with rivaroxaban, patients who received apixaban had a 43% reduced risk of stroke or embolism.
From the Journals
New deep dive into Paxlovid interactions with CVD meds
The review tackles potential drug-drug interactions with the antiviral drug and today’s most commonly prescribed cardiovascular drugs.